Back to today’s briefing

Story perspectives

Shingles Vaccine Cuts Heart Attack Risk by 26%

5/6/2025

50 5

Summary

Story summary

A groundbreaking South Korean study involving over 1 million adults aged 50 and older reveals that the shingles vaccine, Zostavax, can lower the risk of heart attacks and strokes by 26%, reducing overall cardiovascular events by 23% for up to eight years. This significant finding particularly benefits men and younger adults, paving the way for further exploration of the newer Shingrix vaccine.

1 of 1

Story summary

A groundbreaking South Korean study involving over 1 million adults aged 50 and older reveals that the shingles vaccine, Zostavax, can lower the risk of heart attacks and strokes by 26%, reducing overall cardiovascular events by 23% for up to eight years. This significant finding particularly benefits men and younger adults, paving the way for further exploration of the newer Shingrix vaccine.